Minerva Neurosciences (NERV) Financials

Minerva Neurosciences logo
$2.16 -0.04 (-1.82%)
Closing price 04:00 PM Eastern
Extended Trading
$2.17 +0.01 (+0.42%)
As of 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Minerva Neurosciences

Annual Income Statements for Minerva Neurosciences

This table shows Minerva Neurosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-27 -31 -32 -50 -72 1.94 -50 -32 -30 1.44 -293
Consolidated Net Income / (Loss)
-27 -31 -32 -50 -72 1.94 -50 -32 -30 1.44 -293
Net Income / (Loss) Continuing Operations
-27 -31 -32 -50 -72 1.94 -50 -32 -30 1.44 -293
Total Pre-Tax Income
-27 -31 -41 -50 -74 1.94 -52 0.00 0.00 1.44 -293
Total Operating Income
-26 -30 -41 -52 -76 1.85 -45 -25 -23 -22 -15
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 41 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 41 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
26 30 41 52 76 39 45 25 23 22 15
Selling, General & Admin Expense
7.58 9.75 11 17 18 17 13 11 10 9.95 9.34
Research & Development Expense
19 20 30 35 58 22 32 15 13 12 5.76
Total Other Income / (Expense), net
-0.97 -0.85 0.27 1.56 1.43 0.09 -6.34 -6.88 -6.85 23 -278
Interest Expense
- - - - - 0.00 6.33 7.41 8.28 4.56 0.00
Interest & Investment Income
-0.96 -0.83 0.33 1.56 1.46 0.16 0.02 0.56 1.44 1.27 0.95
Other Income / (Expense), net
-0.02 -0.02 -0.06 -0.00 -0.03 -0.07 -0.03 -0.03 0.00 27 -279
Other Gains / (Losses), net
- - - - - - - - -0.04 -0.00 -0.06
Basic Earnings per Share
($1.16) ($0.99) ($0.83) ($1.29) ($1.85) $0.05 ($9.35) ($6.01) ($4.61) $0.19 ($34.67)
Weighted Average Basic Shares Outstanding
23.41M 31.51M 37.94M 38.79M 39.01M 40.82M 5.34M 5.34M 6.51M 7.57M 8.46M
Diluted Earnings per Share
($1.16) ($0.99) ($0.83) ($1.29) ($1.85) $0.05 ($9.35) ($6.01) ($4.61) $0.19 ($34.67)
Weighted Average Diluted Shares Outstanding
23.41M 31.51M 37.94M 38.79M 39.01M 40.92M 5.34M 5.34M 6.51M 7.57M 8.46M
Weighted Average Basic & Diluted Shares Outstanding
23.41M 31.51M 37.94M 38.79M 39.01M 42.72M 42.72M 5.34M 6.99M 6.99M 43.27M

Quarterly Income Statements for Minerva Neurosciences

This table shows Minerva Neurosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-8.57 -8.23 23 -4.27 -3.75 -3.26 -2.74 -284 -125 17 96
Consolidated Net Income / (Loss)
-8.57 -8.23 23 -4.27 -3.75 -3.26 -2.74 -284 -125 17 101
Net Income / (Loss) Continuing Operations
-8.57 -8.23 23 -4.27 -3.75 -3.26 -2.74 -284 -125 17 101
Total Pre-Tax Income
-8.57 -8.23 23 -4.28 -3.74 -3.24 -2.74 -284 -125 17 101
Total Operating Income
-6.68 -6.28 -4.37 -4.52 -3.90 -3.37 -2.84 -4.98 -17 -11 -9.43
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
6.68 6.28 4.37 4.52 3.90 3.37 2.84 4.98 17 11 9.43
Selling, General & Admin Expense
2.51 2.42 2.48 2.54 2.54 2.08 1.92 2.81 11 3.45 4.28
Research & Development Expense
4.17 3.86 1.89 1.98 1.36 1.30 0.93 2.17 5.25 7.19 5.16
Total Other Income / (Expense), net
-1.89 -1.96 27 0.24 0.16 0.14 0.11 -279 -109 28 110
Interest Expense
2.25 2.31 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Interest & Investment Income
0.36 0.36 0.31 0.24 0.16 0.14 0.11 0.55 0.63 0.57 0.59
Other Income / (Expense), net
0.01 -0.00 27 -0.00 0.00 0.00 0.00 - -109 28 110
Other Gains / (Losses), net
- - -0.01 - -0.01 -0.02 -0.01 -0.02 -0.00 -0.01 -0.01
Net Income / (Loss) Attributable to Noncontrolling Interest
- - - - - 0.00 0.00 - - 0.82 5.08
Basic Earnings per Share
($1.13) ($1.09) $2.97 ($0.56) ($0.50) ($0.43) ($0.36) ($33.38) ($2.86) $0.36 $1.94
Weighted Average Basic Shares Outstanding
7.57M 7.57M 7.57M 7.57M 7.57M 7.57M 7.57M 8.46M 43.90M 46.60M 49.29M
Diluted Earnings per Share
($1.13) ($1.09) $2.97 ($0.56) ($0.50) ($0.43) ($0.36) ($33.38) ($2.86) ($0.14) ($0.19)
Weighted Average Diluted Shares Outstanding
7.57M 7.57M 7.57M 7.57M 7.57M 7.57M 7.57M 8.46M 43.90M 79.10M 75.25M
Weighted Average Basic & Diluted Shares Outstanding
6.99M 6.99M 6.99M 6.99M 6.99M 6.99M 6.99M 43.27M 46.59M 47.75M 49.84M

Annual Cash Flow Statements for Minerva Neurosciences

This table details how cash moves in and out of Minerva Neurosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-4.26 69 -57 24 -29 3.94 35 -25 4.82 -20 61
Net Cash From Operating Activities
-24 -26 3.09 -42 -43 -34 -25 -25 -15 -20 -14
Net Cash From Continuing Operating Activities
-24 -26 3.09 -42 -43 -34 -25 -25 -15 -20 -14
Net Income / (Loss) Continuing Operations
-27 -31 -32 -50 -72 1.94 -50 -32 -30 1.44 -293
Consolidated Net Income / (Loss)
-27 -31 -32 -50 -72 1.94 -50 -32 -30 1.44 -293
Depreciation Expense
0.02 0.02 0.01 0.02 0.02 0.02 - 0.00 0.01 0.01 0.01
Amortization Expense
0.62 0.45 0.02 -0.08 0.91 0.07 0.10 0.01 0.03 0.02 0.00
Non-Cash Adjustments To Reconcile Net Income
1.80 3.94 4.73 7.56 27 8.84 27 12 10 -21 281
Changes in Operating Assets and Liabilities, net
0.37 0.95 30 0.73 0.46 -45 -2.13 -4.56 5.08 -0.50 -0.74
Net Cash From Investing Activities
-18 18 -107 69 14 25 0.00 -0.02 0.00 0.00 0.00
Net Cash From Continuing Investing Activities
-18 18 -107 69 14 25 0.00 -0.02 0.00 0.00 0.00
Net Cash From Financing Activities
38 77 47 -3.34 0.52 13 60 -0.00 20 0.00 74
Net Cash From Continuing Financing Activities
38 77 47 -3.34 0.52 13 60 -0.00 20 0.00 74
Repurchase of Common Equity
0.00 -3.83 -2.94 - 0.00 -0.46 - 0.00 -0.40 0.00 -5.39
Issuance of Common Equity
31 1.00 45 - 0.00 13 - 0.00 20 0.00 80
Other Financing Activities, net
-2.47 81 10 0.66 0.52 1.14 60 -0.00 0.00 0.00 -0.16

Quarterly Cash Flow Statements for Minerva Neurosciences

This table details how cash moves in and out of Minerva Neurosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-6.09 -3.94 -4.35 -5.17 -4.07 -2.04 -2.96 70 -50 -8.01 -4.44
Net Cash From Operating Activities
-6.09 -3.94 -4.35 -5.17 -4.07 -2.04 -2.92 -4.48 -5.43 -13 -8.15
Net Cash From Continuing Operating Activities
-6.09 -3.94 -4.35 -5.17 -4.07 -2.04 -2.92 -4.48 -5.43 -13 -8.15
Net Income / (Loss) Continuing Operations
-8.57 -8.23 23 -4.27 -3.75 -3.26 -2.74 -284 -125 17 101
Consolidated Net Income / (Loss)
-8.57 -8.23 23 -4.27 -3.75 -3.26 -2.74 -284 -125 17 101
Amortization Expense
0.01 0.01 0.00 - 0.00 - - - -0.14 -0.40 -0.40
Non-Cash Adjustments To Reconcile Net Income
2.98 2.92 -27 0.75 0.57 0.63 -0.16 280 118 -29 -108
Changes in Operating Assets and Liabilities, net
-0.51 1.37 0.28 -1.65 -0.89 0.58 -0.01 -0.42 2.26 -1.73 -0.12
Net Cash From Investing Activities
0.00 - - - 0.00 - - - -45 -4.83 -5.73
Net Cash From Continuing Investing Activities
0.00 - - - 0.00 - - - -45 -4.83 -5.73
Purchase of Investments
- - - - 0.00 - - - -45 -9.83 -23
Sale and/or Maturity of Investments
- - - - - - - - - - 18
Net Cash From Financing Activities
0.00 - - - 0.00 - -0.05 74 1.08 10 9.44
Net Cash From Continuing Financing Activities
0.00 - - - 0.00 - -0.05 74 1.08 10 9.44
Other Financing Activities, net
- - - - 0.00 - - - 1.17 10 -0.56

Annual Balance Sheets for Minerva Neurosciences

This table presents Minerva Neurosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
83 133 184 139 77 58 77 55 57 37 98
Total Current Assets
33 84 130 90 47 27 62 40 42 22 83
Cash & Equivalents
14 83 26 50 21 25 61 36 41 21 82
Restricted Cash
0.08 0.08 0.08 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10
Short-Term Investments
18 0.00 102 38 24 - - - - - 0.00
Prepaid Expenses
1.20 0.80 1.30 1.92 1.18 1.98 1.35 0.85 0.99 0.81 0.70
Other Current Assets
- - - - - - 0.00 3.12 0.00 0.00 0.00
Plant, Property, & Equipment, net
0.03 0.01 0.05 0.03 0.02 0.00 0.00 0.02 0.01 0.01 0.00
Total Noncurrent Assets
49 49 54 49 30 30 15 15 15 15 15
Goodwill
15 15 15 15 15 15 15 15 15 15 15
Intangible Assets
34 34 34 34 15 15 0.05 0.04 0.02 0.00 0.00
Other Noncurrent Operating Assets
- 0.00 0.01 0.01 0.28 0.12 - - - - 0.00
Total Liabilities & Shareholders' Equity
83 133 184 139 77 58 77 55 57 37 98
Total Liabilities
27 27 52 49 50 4.96 69 75 85 63 234
Total Current Liabilities
5.32 9.69 6.84 3.61 6.63 3.16 2.82 1.38 3.34 2.84 2.29
Accounts Payable
3.89 2.28 2.88 3.61 6.46 3.05 2.82 1.38 3.34 2.84 2.29
Total Noncurrent Liabilities
22 17 45 45 43 1.80 66 74 82 60 231
Other Noncurrent Operating Liabilities
- 0.00 0.03 0.03 0.11 - 66 74 82 60 231
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
- - - - - - - - - 0.00 4.96
Total Equity & Noncontrolling Interests
55 106 132 90 28 53 7.98 -20 -28 -26 -141
Total Preferred & Common Equity
55 106 132 90 28 53 7.98 -20 -28 -26 -141
Total Common Equity
55 106 132 90 28 53 7.98 -20 -28 -26 -141
Common Stock
157 239 296 305 315 337 343 347 368 370 548
Retained Earnings
-102 -133 -164 -215 -287 -285 -335 -367 -397 -395 -689

Quarterly Balance Sheets for Minerva Neurosciences

This table presents Minerva Neurosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
63 51 46 43 33 30 28 94 95 98
Total Current Assets
48 36 31 28 18 16 13 79 80 83
Cash & Equivalents
47 35 31 27 17 15 12 33 25 20
Restricted Cash
0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10
Short-Term Investments
- - - - - - - 45 51 57
Prepaid Expenses
1.22 0.70 0.43 1.31 0.53 0.20 0.63 0.94 4.37 6.36
Other Current Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Plant, Property, & Equipment, net
0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
15 15 15 15 15 15 15 15 15 15
Goodwill
15 15 15 15 15 15 15 15 15 15
Intangible Assets
0.02 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.20 0.05 0.49 0.00
Total Liabilities & Shareholders' Equity
63 51 46 43 33 30 28 94 95 98
Total Liabilities
83 87 91 64 62 63 63 343 297 184
Total Current Liabilities
3.35 2.83 4.20 4.48 1.95 2.53 2.67 4.48 3.96 2.53
Accounts Payable
3.35 2.83 4.20 4.48 1.95 2.53 2.67 4.48 3.96 2.53
Total Noncurrent Liabilities
80 84 87 60 60 60 60 339 293 182
Other Noncurrent Operating Liabilities
80 84 87 60 60 60 60 339 293 182
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
- - - - - - - 4.96 12 12
Total Equity & Noncontrolling Interests
-20 -37 -44 -22 -29 -32 -35 -254 -213 -98
Total Preferred & Common Equity
-20 -37 -44 -22 -29 -32 -35 -254 -213 -98
Total Common Equity
-20 -37 -44 -22 -29 -32 -35 -254 -213 -98
Common Stock
368 369 369 369 370 370 371 560 583 598
Retained Earnings
-388 -405 -414 -391 -399 -402 -405 -814 -797 -696

Annual Metrics And Ratios for Minerva Neurosciences

This table displays calculated financial ratios and metrics derived from Minerva Neurosciences' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
24,721,143.00 34,807,213.00 38,700,693.00 38,871,467.00 39,025,471.00 42,674,491.00 42,721,566.00 5,340,193.00 6,993,406.00 6,993,406.00 6,993,406.00
DEI Adjusted Shares Outstanding
3,090,143.00 4,350,902.00 4,837,587.00 4,858,933.00 4,878,184.00 5,334,311.00 5,340,196.00 5,340,193.00 6,993,406.00 6,993,406.00 6,993,406.00
DEI Earnings Per Adjusted Shares Outstanding
-8.76 -7.14 -6.52 -10.33 -14.80 0.36 -9.35 -6.01 -4.29 0.21 -41.96
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
51.81% -16.73% -38.48% -25.74% -44.73% 102.49% -2,523.62% 44.26% 8.56% 120.59% -6,291.91%
EBIT Growth
52.39% -15.65% -36.45% -25.49% -46.70% 102.34% -2,651.10% 44.36% 8.47% 120.46% -6,321.43%
NOPAT Growth
52.42% -15.63% -36.37% -25.65% -46.66% 103.48% -1,819.56% 44.38% 8.37% -35.00% 51.61%
Net Income Growth
52.41% -14.64% -1.54% -59.16% -43.87% 102.69% -2,671.45% 35.66% 6.55% 104.80% -20,492.68%
EPS Growth
74.05% 14.66% 16.16% -55.42% -43.41% 102.70% -2,671.45% 35.72% 23.29% 104.12% -18,347.37%
Operating Cash Flow Growth
32.51% -5.84% 112.04% -1,456.08% -3.55% 22.13% 27.26% -0.18% 40.01% -32.23% 30.89%
Free Cash Flow Firm Growth
65.64% -7.89% 102.54% -7,296.13% 9.20% -32.87% 211.02% -129.64% 79.53% -1,406.53% 463.33%
Invested Capital Growth
0.16% -4.11% -92.74% -5.59% -938.52% 249.69% -294.37% -6.31% -23.57% 32.12% -362.70%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-2.31% -4.13% -1.22% -8.50% -29.95% 106.27% -96.48% 39.21% -10.01% 119.42% -1,910.57%
EBIT Q/Q Growth
-3.01% -3.66% -0.86% -8.61% -32.86% 105.68% -95.70% 39.19% -10.00% 119.31% -1,909.86%
NOPAT Q/Q Growth
-2.95% -3.58% -0.72% -8.60% -32.81% 108.43% -95.56% 39.26% 23.00% 10.82% -3.14%
Net Income Q/Q Growth
-3.82% -3.21% 23.28% -36.31% -30.13% 109.40% -38.92% 31.23% -8.29% 143.45% -1,991.76%
EPS Q/Q Growth
-48.72% 5.71% 26.55% -38.71% -30.28% 107.25% -38.92% 31.24% -25.96% 143.18% -1,774.05%
Operating Cash Flow Q/Q Growth
-6.99% -9.95% 0.52% -2.16% -11.22% 17.19% 8.64% 2.85% -14.58% 4.05% 4.83%
Free Cash Flow Firm Q/Q Growth
0.00% -13.29% -95.17% 19.86% -3.05% 16.01% 3.31% -18.17% 65.65% -2.11% 1,485.31%
Invested Capital Q/Q Growth
-2.88% 1.98% 128.72% -41.23% -303.39% 7.08% -40.60% -3.03% -3.61% 2.37% -364.56%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 4.54% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 4.49% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 4.32% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 4.71% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 77.07% 100.00% 96.97% 100.00% 96.51% 0.00% 0.00% 99.87% 100.02%
Interest Burden Percent
103.66% 102.75% 99.21% 96.98% 98.08% 109.06% 113.90% 0.00% 0.00% 30.46% 99.68%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 40.90% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 40.63% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% -36.07% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-50.71% -38.49% -26.54% -45.23% -122.30% 4.83% -164.60% 532.99% 123.78% -5.31% 363.42%
Cash Return on Invested Capital (CROIC)
-55.64% -61.24% 2.96% -1,616.84% 0.00% -160.02% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 2.63% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 2.87% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-50.71% -38.49% -26.54% -45.23% -122.30% 4.83% -164.60% 532.99% 123.78% -5.31% 374.59%
Return on Equity Simple (ROE_SIMPLE)
-48.95% -29.29% -23.95% -55.58% -259.84% 3.69% -625.73% 160.35% 105.44% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-18 -21 -29 -36 -53 1.85 -32 -18 -16 -22 -11
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 4.49% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-43.03% -20.50% -2.66% -12.84% -28.46% 0.26% -42.06% -29.77% -35.80% 74.55% -544.66%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - 56.87% 85.04% 7.51%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 41.99% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 53.53% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 95.51% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-26 -30 -41 -52 -76 1.78 -45 -25 -23 4.73 -294
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-25 -30 -41 -52 -75 1.87 -45 -25 -23 4.75 -294
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.71 3.86 1.78 2.90 9.99 1.90 4.29 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
24.01 7.19 2.84 6.36 0.00 4.42 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 2.43 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 51.45 0.00 0.00 0.00 10.80 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 1.94% 0.00% 0.00% 0.00% 9.26% 0.00%
Enterprise Value to Invested Capital (EV/IC)
3.87 10.58 45.66 80.23 0.00 2.73 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 1.81 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 39.81 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 41.81 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 40.29 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 33.90 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 209.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.18 0.08 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.15 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.38 -0.60 -0.86 -0.98 -1.14 -0.89 -1.42 8.05 1.59 1.15 0.64
Leverage Ratio
1.41 1.34 1.33 1.46 1.84 1.68 2.22 -10.97 -2.31 -1.74 -0.84
Compound Leverage Factor
1.47 1.37 1.32 1.41 1.80 1.83 2.53 0.00 0.00 -0.53 -0.83
Debt to Total Capital
15.23% 7.58% 2.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
2.20% 4.23% 2.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
13.03% 3.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.65%
Common Equity to Total Capital
84.77% 92.42% 97.08% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 103.65%
Debt to EBITDA
-0.39 -0.29 -0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.88 2.50 3.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
-0.33 -0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
-0.54 -0.41 -0.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
1.22 3.52 4.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
-0.47 -0.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.94 7.62 1.50 0.58 -4.44 6.47 -6.80 -9.92 -9.99 -13.71 -18.69
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.07%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
6.29 8.66 18.94 24.94 7.11 8.68 22.07 29.15 12.57 7.85 36.28
Quick Ratio
6.05 8.57 18.74 24.38 6.92 8.02 21.55 26.20 12.25 7.53 35.93
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-18 -20 0.50 -36 -33 -44 48 -14 -2.93 -44 160
Operating Cash Flow to CapEx
0.00% 0.00% 5,902.41% 0.00% 0.00% 0.00% 0.00% -150,956.41% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 7.64 -1.93 -0.35 -9.68 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -3.89 -3.33 -1.79 -4.29 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -3.89 -3.33 -1.79 -4.29 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.61 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
33 32 2.30 2.17 -18 27 -53 -56 -69 -47 -218
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 9.12 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.05 -1.36 -29 -0.13 -20 45 -80 -3.34 -13 22 -171
Enterprise Value (EV)
128 335 105 174 232 74 -27 -28 2.00 -5.93 -49
Market Capitalization
150 409 234 262 277 100 34 8.49 43 16 28
Book Value per Share
$2.24 $3.04 $3.40 $2.32 $0.71 $1.23 $0.19 ($3.75) ($4.07) ($3.67) ($20.13)
Tangible Book Value per Share
$0.25 $1.64 $2.13 $1.06 ($0.06) $0.53 ($0.16) ($6.54) ($6.20) ($5.80) ($22.25)
Total Capital
65 115 136 90 28 53 7.98 -20 -28 -26 -136
Total Debt
9.94 8.69 3.96 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
8.50 3.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-22 -74 -129 -88 -46 -25 -61 -36 -41 -21 -82
Capital Expenditures (CapEx)
0.00 0.00 0.05 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-2.69 -4.03 -1.58 -1.69 -5.45 -1.18 -1.47 2.59 -2.35 -2.03 -1.59
Debt-free Net Working Capital (DFNWC)
30 79 127 86 41 24 59 39 39 19 81
Net Working Capital (NWC)
28 74 123 86 41 24 59 39 39 19 81
Net Nonoperating Expense (NNE)
8.80 9.91 2.70 14 19 -0.09 18 14 14 -23 283
Net Nonoperating Obligations (NNO)
-22 -74 -129 -88 -46 -25 -61 -36 -41 -21 -82
Total Depreciation and Amortization (D&A)
0.64 0.47 0.03 -0.06 0.93 0.09 0.10 0.01 0.03 0.02 0.01
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% -2.86% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 58.97% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 58.97% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($9.28) ($7.92) ($6.64) ($10.32) ($14.80) $0.40 ($9.36) ($6.01) ($4.61) $0.19 ($34.67)
Adjusted Weighted Average Basic Shares Outstanding
3.47M 4.41M 4.84M 4.88M 4.90M 5.10M 5.34M 5.34M 6.51M 7.57M 8.46M
Adjusted Diluted Earnings per Share
($9.28) ($7.92) ($6.64) ($10.32) ($14.80) $0.40 ($9.36) ($6.01) ($4.61) $0.19 ($34.67)
Adjusted Weighted Average Diluted Shares Outstanding
3.47M 4.41M 4.84M 4.88M 4.90M 5.11M 5.34M 5.34M 6.51M 7.57M 8.46M
Adjusted Basic & Diluted Earnings per Share
($9.28) ($7.92) ($6.64) ($10.32) ($14.80) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
2.93M 3.94M 4.74M 4.85M 4.88M 5.34M 5.34M 5.34M 6.99M 6.99M 43.27M
Normalized Net Operating Profit after Tax (NOPAT)
-18 -21 -29 -36 -53 1.29 -32 -18 -16 -15 -11
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 3.14% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 4.71% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -7.18 -3.41 -2.79 1.04 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -5.02 -2.38 -1.95 -4.79 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -7.18 -3.41 -2.79 1.04 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -5.02 -2.39 -1.95 -4.79 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -12.34% -9.34% 0.00% 0.00% 23.48% 0.00% 0.00% -1.32% 0.00% -1.84%

Quarterly Metrics And Ratios for Minerva Neurosciences

This table displays calculated financial ratios and metrics derived from Minerva Neurosciences' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
6,993,406.00 6,993,406.00 6,993,406.00 6,993,406.00 6,993,406.00 6,993,406.00 6,993,406.00 6,993,406.00 43,274,398.00 46,588,709.00 47,747,559.00
DEI Adjusted Shares Outstanding
6,993,406.00 6,993,406.00 6,993,406.00 6,993,406.00 6,993,406.00 6,993,406.00 6,993,406.00 6,993,406.00 43,274,398.00 46,588,709.00 47,747,559.00
DEI Earnings Per Adjusted Shares Outstanding
-1.23 -1.18 3.22 -0.61 -0.54 -0.47 -0.39 -40.56 -2.90 0.36 2.00
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-24.66% -39.06% 465.95% 36.89% 41.50% 46.25% -112.80% -10.14% -3,133.84% 589.60% 3,609.27%
EBIT Growth
-24.63% -38.99% 465.39% 36.94% 41.54% 46.29% -112.81% -10.14% -3,129.21% 601.19% 3,621.66%
NOPAT Growth
-24.93% -38.88% -2.62% 55.86% 41.59% 46.25% 54.40% -10.16% -327.16% -350.58% -373.81%
Net Income Growth
-22.93% -32.97% 387.88% 52.65% 56.20% 60.42% -112.19% -6,540.09% -3,241.47% 636.01% 3,771.58%
EPS Growth
13.74% 2.68% 388.35% 59.71% 55.75% 60.55% -112.12% -5,860.71% -472.00% 67.44% 47.22%
Operating Cash Flow Growth
-5,180.68% -1.69% 9.44% 13.76% 33.18% 48.13% 33.00% 13.28% -33.28% -553.47% -179.47%
Free Cash Flow Firm Growth
30.36% 121.81% -380.93% -519.07% -770.35% -555.39% 85.62% 757.55% 1,071.19% 820.36% 3,302.13%
Invested Capital Growth
-14.05% -17.18% 27.97% 32.12% 34.92% 37.12% 2.76% -362.70% -603.10% -483.53% -246.69%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
6.92% 5.91% 454.10% -120.35% 13.71% 13.55% 15.71% -75.18% -2,433.40% 113.09% 504.17%
EBIT Q/Q Growth
6.91% 5.90% 453.57% -120.36% 13.71% 13.55% 15.70% -75.14% -2,429.96% 113.42% 492.32%
NOPAT Q/Q Growth
34.78% 6.05% 0.63% 27.51% 13.69% 13.55% 15.70% -75.14% -234.66% 8.81% 11.36%
Net Income Q/Q Growth
5.03% 3.91% 373.43% -118.98% 12.15% 13.17% 15.79% -10,237.92% 55.79% 113.93% 476.81%
EPS Q/Q Growth
18.71% 3.54% 372.48% -118.86% 10.71% 14.00% 16.28% -9,172.22% 91.43% 95.10% -35.71%
Operating Cash Flow Q/Q Growth
-1.72% 35.39% -10.54% -18.72% 21.19% 49.85% -42.80% -53.66% -21.12% -145.89% 38.93%
Free Cash Flow Firm Q/Q Growth
-32.04% 61.44% -446.55% -10.22% -8.71% -9.67% 89.06% 5,141.06% 60.56% -18.65% -51.36%
Invested Capital Q/Q Growth
-2.93% -5.55% 36.00% 2.37% 1.31% -1.97% 1.03% -364.56% -49.97% 15.37% 41.20%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 99.94% 99.74% 100.22% 100.65% 100.23% 100.01% 100.00% 99.92% 99.99%
Interest Burden Percent
128.34% 131.06% 101.41% 94.70% 95.94% 95.95% 96.25% 5,693.90% 99.50% 103.37% 100.59%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
100.00% 118.05% 15.88% -5.31% -19.03% -29.32% 49.87% 363.42% 298.40% 337.53% 483.30%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
100.00% 118.05% 15.88% -5.31% -19.03% -29.32% 49.87% 374.59% 303.72% 354.49% 530.45%
Return on Equity Simple (ROE_SIMPLE)
86.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-4.68 -4.39 -4.37 -3.17 -2.73 -2.36 -1.99 -3.49 -12 -11 -9.43
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-10.96% -9.26% 73.01% -3.54% -3.90% -3.87% -3.86% -539.52% -238.05% 61.97% 246.40%
Return On Investment Capital (ROIC_SIMPLE)
12.78% 9.88% 20.15% 12.32% 9.37% 7.36% 5.76% 2.48% 4.59% 4.99% 9.67%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-6.68 -6.28 22 -4.52 -3.90 -3.37 -2.84 -4.98 -126 17 100
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-6.67 -6.27 22 -4.52 -3.90 -3.37 -2.84 -4.98 -126 17 100
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 10.80 1.90 1.07 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 9.26% 52.61% 93.36% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.72 0.95 1.09
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
1.12 1.45 1.77 1.15 0.80 0.60 0.69 0.64 0.34 0.39 0.74
Leverage Ratio
-1.62 -1.99 -2.54 -1.74 -1.27 -1.00 -1.26 -0.84 -0.46 -0.54 -1.05
Compound Leverage Factor
-2.07 -2.61 -2.58 -1.64 -1.22 -0.96 -1.21 -47.64 -0.45 -0.56 -1.06
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.65% -1.99% -5.83% -13.69%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 103.65% 101.99% 105.83% 113.69%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.00 -12.10 -10.25 -14.53 -16.73 -18.26 -19.94 -8.95 -15.14 -9.66 -5.04
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.07% -1.78% -5.02% -9.75%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
12.58 7.47 6.23 7.85 9.21 6.15 4.87 36.28 17.65 20.14 33.02
Quick Ratio
12.30 7.35 5.92 7.53 8.88 6.03 4.60 35.93 17.42 19.02 30.46
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
4.13 6.67 -23 -25 -28 -30 -3.32 168 269 219 106
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
1.84 2.89 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-2.71 -1.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-2.71 -1.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-72 -75 -48 -47 -47 -47 -47 -218 -327 -277 -163
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-8.81 -11 19 22 25 28 1.33 -171 -281 -229 -116
Enterprise Value (EV)
0.00 -8.67 -7.96 -5.93 -5.50 -3.32 2.33 -49 188 195 95
Market Capitalization
0.00 22 19 16 12 12 15 28 261 259 160
Book Value per Share
($4.83) ($6.36) ($3.10) ($3.67) ($4.17) ($4.59) ($4.94) ($20.13) ($5.87) ($4.58) ($2.04)
Tangible Book Value per Share
($6.80) ($8.49) ($5.22) ($5.80) ($6.29) ($6.72) ($7.07) ($22.25) ($6.21) ($4.90) ($2.35)
Total Capital
-37 -44 -22 -26 -29 -32 -35 -136 -249 -202 -86
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-35 -31 -27 -21 -17 -15 -12 -82 -78 -75 -77
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-2.13 -3.78 -3.18 -2.03 -1.41 -2.33 -2.04 -1.59 -3.54 0.41 3.84
Debt-free Net Working Capital (DFNWC)
33 27 23 19 16 13 10 81 75 76 81
Net Working Capital (NWC)
33 27 23 19 16 13 10 81 75 76 81
Net Nonoperating Expense (NNE)
3.89 3.84 -27 1.11 1.02 0.90 0.75 280 114 -28 -110
Net Nonoperating Obligations (NNO)
-35 -31 -27 -21 -17 -15 -12 -82 -78 -75 -77
Total Depreciation and Amortization (D&A)
0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 -0.14 -0.40 -0.40
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($1.13) ($1.09) $2.97 ($0.56) ($0.50) ($0.43) ($0.36) ($33.38) ($2.86) $0.36 $1.94
Adjusted Weighted Average Basic Shares Outstanding
7.57M 7.57M 7.57M 7.57M 7.57M 7.57M 7.57M 8.46M 43.90M 46.60M 49.29M
Adjusted Diluted Earnings per Share
($1.13) ($1.09) $2.97 ($0.56) ($0.50) ($0.43) ($0.36) ($33.38) ($2.86) ($0.14) ($0.19)
Adjusted Weighted Average Diluted Shares Outstanding
7.57M 7.57M 7.57M 7.57M 7.57M 7.57M 7.57M 8.46M 43.90M 79.10M 75.25M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
6.99M 6.99M 6.99M 6.99M 6.99M 6.99M 6.99M 43.27M 46.59M 47.75M 49.84M
Normalized Net Operating Profit after Tax (NOPAT)
-4.68 -4.39 -3.06 -3.17 -2.73 -2.36 -1.99 -3.49 -12 -7.45 -6.60
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-2.97 -2.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-2.08 -1.90 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-2.97 -2.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-2.08 -1.90 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.32% -1.84% -1.32% -1.42% -1.91%

Financials Breakdown Chart

Key Financial Trends

Minerva Neurosciences’ latest statements show a cash-rich but financially fragile development-stage company. Revenue has remained at $0 in every reported quarter, leaving the company dependent on financing, investment income and nonrecurring transactions while it funds research and development.

In Q2 2026, Minerva reported $17.5 million of net income attributable to common shareholders, compared with a $125.4 million loss in Q1. However, the improvement was driven by $27.6 million of other income, not operating performance. Operating expenses were $10.6 million, including $7.2 million of research and development costs, and operating income remained negative at $10.6 million.

Liquidity improved substantially from 2025 levels. At June 30, 2026, the company held $24.7 million of cash, $50.6 million of short-term investments and $100,000 of restricted cash. Nevertheless, Q2 operating cash flow was negative $13.3 million, and first-half operating cash burn totaled approximately $18.8 million. The balance sheet also showed $296.6 million of total liabilities against negative common equity of $213.3 million, highlighting significant balance-sheet risk.

  • Liquidity is materially stronger than in mid-2025: cash and short-term investments totaled approximately $75.3 million at June 30, 2026, compared with cash of only $12.3 million at September 30, 2025.
  • Q2 operating expenses declined sequentially: total operating expenses fell to $10.6 million from $16.7 million in Q1 2026, helped by lower SG&A spending.
  • Research and development spending increased to $7.2 million in Q2 2026 from $5.3 million in Q1, which could support advancement of the company’s clinical pipeline if the spending produces successful results.
  • Q2 financing activities provided $10.2 million of cash, partially offsetting operating and investing cash outflows.
  • Q2 net income swung to $17.5 million from a $125.4 million loss in Q1, but the result was primarily caused by other income rather than recurring revenue or operating profitability.
  • Interest and investment income remains a useful source of cash generation, reaching $569,591 in Q2 2026, although it is not a substitute for commercial revenue.
  • The company continues to report no revenue, gross profit or operating profit across the periods provided, so valuation depends heavily on clinical progress and future financing or partnership opportunities.
  • Operating cash flow remains negative: Minerva used $13.3 million in operating activities during Q2 and approximately $18.8 million during the first half of 2026.
  • The balance sheet carries substantial liabilities and negative equity. Total liabilities were $296.6 million at June 30, 2026, while total common equity was negative $213.3 million.
  • Share-count figures indicate significant dilution and require close monitoring. Basic weighted-average shares rose to 46.6 million in Q2 2026 from roughly 7.6 million in 2025 periods; the reported diluted share figure of 79.1 million and negative diluted EPS also suggest that investors should review the company’s capital structure and filing footnotes carefully.
11/17/26 06:33 PM ETAI Generated. May Contain Errors.

Minerva Neurosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Minerva Neurosciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Minerva Neurosciences' net income appears to be on a downward trend, with a most recent value of -$293.42 million in 2025, falling from -$27.08 million in 2015. The previous period was $1.44 million in 2024. Find out what analysts predict for Minerva Neurosciences in the coming months.

Minerva Neurosciences' total operating income in 2025 was -$15.10 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $15.10 million

Over the last 10 years, Minerva Neurosciences' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

In the past 12 quarters, Minerva Neurosciences' cash and equivalents has ranged from $12.29 million in Q3 2025 to $46.90 million in Q3 2023, and is currently $20.22 million as of their latest financial filing in Q3 2026.

Minerva Neurosciences had total debt of $0.00 at the end of 2025, compared with none in 2024, and a 100.0% decrease since 2015.

Over the last 10 years, Minerva Neurosciences' book value per share changed from 2.24 in 2015 to -20.13 in 2025.



Financial statements for NASDAQ:NERV last updated on 11/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners